{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T04:03:39Z","timestamp":1779249819950,"version":"3.51.4"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T00:00:00Z","timestamp":1715040000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T00:00:00Z","timestamp":1715040000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    We investigated data from 180 consecutive patients with myelodysplastic\/myeloproliferative neoplasms with\n                    <jats:italic>SF3B1<\/jats:italic>\n                    mutation and thrombocytosis (MDS\/MPN-\n                    <jats:italic>SF3B1<\/jats:italic>\n                    -T) who were diagnosed according to the 2022 World Health Organization (WHO) classification of myeloid neoplasms to identify covariates associated with survival. At a median follow-up of 48 months (95% confidence interval [CI] 35\u201361 months), the median survival was 69 months (95% CI 59\u201379 months). Patients with bone marrow ring sideroblasts (RS)\u2009&lt;\u200915% had shorter median overall survival (OS) than did those with bone marrow RS\u2009\u2265\u200915% (41 months [95% CI 32\u201350 months]\n                    <jats:italic>versus<\/jats:italic>\n                    76 months [95% CI 59\u201393 months];\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.001). According to the univariable analyses of OS, age\u2009\u2265\u200965 years (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.001), hemoglobin concentration (Hb)\u2009&lt;\u200980\u2009g\/L (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.090), platelet count (PLT)\u2009\u2265\u2009800\u2009\u00d7\u200910E\u2009+\u20099\/L (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.087), bone marrow RS\u2009&lt;\u200915% (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.001), the Revised International Prognostic Scoring System (IPSS-R) cytogenetic category intermediate\/poor\/very poor (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.005),\n                    <jats:italic>SETBP1<\/jats:italic>\n                    mutation (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.061) and\n                    <jats:italic>SRSF2<\/jats:italic>\n                    mutation (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.001) were associated with poor survival. Based on variables selected from univariable analyses, two separate survival prediction models, a clinical survival model, and a clinical-molecular survival model, were developed using multivariable analyses with the minimum value of the Akaike information criterion (AIC) to specifically predict outcomes in patients with MDS\/MPN-\n                    <jats:italic>SF3B1<\/jats:italic>\n                    -T according to the 2022 WHO classification.\n                  <\/jats:p>","DOI":"10.1038\/s41375-024-02262-2","type":"journal-article","created":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T07:02:05Z","timestamp":1715065325000},"page":"1334-1341","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Predicting survival in patients with myelodysplastic\/myeloproliferative neoplasms with SF3B1 mutation and thrombocytosis"],"prefix":"10.1038","volume":"38","author":[{"given":"Fuhui","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiejun","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8291-9883","authenticated-orcid":false,"given":"Bing","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiqiang","family":"Qu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lijuan","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peihong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7550-8832","authenticated-orcid":false,"given":"Wenyu","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingyan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junjie","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaofei","family":"Ai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiao","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert Peter","family":"Gale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-0147-2291","authenticated-orcid":false,"given":"Zefeng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1099-4489","authenticated-orcid":false,"given":"Zhijian","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,5,7]]},"reference":[{"key":"2262_CR1","unstructured":"Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. World Health Organization classification of tumours: pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC Press; 2001."},{"key":"2262_CR2","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1182\/blood-2002-04-1199","volume":"100","author":"JW Vardiman","year":"2002","unstructured":"Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100:2292\u2013302.","journal-title":"Blood"},{"key":"2262_CR3","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1111\/j.1365-2141.2008.07526.x","volume":"144","author":"D Wardrop","year":"2009","unstructured":"Wardrop D, Steensma DP. Is refractory anaemia with ring sideroblasts and thrombocytosis (RARS-T) a necessary or useful diagnostic category? Br J Haematol. 2009;144:809\u201317.","journal-title":"Br J Haematol"},{"key":"2262_CR4","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","volume":"114","author":"JW Vardiman","year":"2009","unstructured":"Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114:937\u201351.","journal-title":"Blood"},{"key":"2262_CR5","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1002\/ajh.24038","volume":"90","author":"MM Patnaik","year":"2015","unstructured":"Patnaik MM, Tefferi A. Refractory anemia with ring sideroblasts and RARS with thrombocytosis. Am J Hematol. 2015;90:549\u201359.","journal-title":"Am J Hematol"},{"key":"2262_CR6","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391\u2013405.","journal-title":"Blood"},{"key":"2262_CR7","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1002\/ajh.25397","volume":"94","author":"MM Patnaik","year":"2019","unstructured":"Patnaik MM, Tefferi A. Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis: \u201c2019 update on diagnosis, risk-stratification, and management\u201d. Am J Hematol. 2019;94:475\u201388.","journal-title":"Am J Hematol"},{"key":"2262_CR8","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.3324\/haematol.2011.053918","volume":"97","author":"J Broseus","year":"2012","unstructured":"Broseus J, Florensa L, Zipperer E, Schnittger S, Malcovati L, Richebourg S, et al. Clinical features and course of refractory anemia with ring sideroblasts associated with marked thrombocytosis. Haematologica. 2012;97:1036\u201341.","journal-title":"Haematologica"},{"key":"2262_CR9","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1038\/leu.2013.120","volume":"27","author":"J Bros\u00e9us","year":"2013","unstructured":"Bros\u00e9us J, Alpermann T, Wulfert M, Florensa Brichs L, Jeromin S, Lippert E, et al. Age, JAK2(V617F) and SF3B1 mutations are the main predicting factors for survival in refractory anaemia with ring sideroblasts and marked thrombocytosis. Leukemia. 2013;27:1826\u201331.","journal-title":"Leukemia"},{"key":"2262_CR10","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1002\/ajh.24332","volume":"91","author":"MM Patnaik","year":"2016","unstructured":"Patnaik MM, Lasho TL, Finke CM, Hanson CA, King RL, Ketterling RP, et al. Predictors of survival in refractory anemia with ring sideroblasts and thrombocytosis (RARS-T) and the role of next-generation sequencing. Am J Hematol. 2016;91:492\u20138.","journal-title":"Am J Hematol"},{"key":"2262_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00622-8","volume":"12","author":"AA Mangaonkar","year":"2022","unstructured":"Mangaonkar AA, Lasho TL, Ketterling RP, Reichard KK, Gangat N, Al-Kali A, et al. Myelodysplastic\/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS\/MPN-RS-T): Mayo-Moffitt collaborative study of 158 patients. Blood Cancer J. 2022;12:26.","journal-title":"Blood Cancer J"},{"key":"2262_CR12","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s12185-023-03592-0","volume":"118","author":"Y Edahiro","year":"2023","unstructured":"Edahiro Y, Ochiai T, Hashimoto Y, Morishita S, Shirane S, Inano T, et al. Clinical characteristics of Japanese patients with myelodysplastic\/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis. Int J Hematol. 2023;118:47\u201353.","journal-title":"Int J Hematol"},{"key":"2262_CR13","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1182\/blood-2022-170734","volume":"140","author":"VA Vardell","year":"2022","unstructured":"Vardell VA, Peters DJ, Tantravahi SK, Patel AB. Myelodysplastic syndrome\/myeloproliferative neoplasm overlap syndromes: a national analysis of overall survival and demographic features. Blood. 2022;140:1350\u20132.","journal-title":"Blood"},{"key":"2262_CR14","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1002\/ajh.26090","volume":"96","author":"MM Patnaik","year":"2021","unstructured":"Patnaik MM, Tefferi A. Myelodysplastic syndromes with ring sideroblasts (MDS-RS) and MDS\/myeloproliferative neoplasm with RS and thrombocytosis (MDS\/MPN-RS-T) - \u201c2021 update on diagnosis, risk-stratification, and management\u201d. Am J Hematol. 2021;96:379\u201394.","journal-title":"Am J Hematol"},{"key":"2262_CR15","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1056\/NEJMoa1103283","volume":"365","author":"E Papaemmanuil","year":"2011","unstructured":"Papaemmanuil E, Cazzola M, Boultwood J, Malcovati L, Vyas P, Bowen D, et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med. 2011;365:1384\u201395.","journal-title":"N Engl J Med"},{"key":"2262_CR16","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1182\/blood-2015-03-633537","volume":"126","author":"L Malcovati","year":"2015","unstructured":"Malcovati L, Karimi M, Papaemmanuil E, Ambaglio I, J\u00e4dersten M, Jansson M, et al. SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts. Blood. 2015;126:233\u201341.","journal-title":"Blood"},{"key":"2262_CR17","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1182\/blood.2020004850","volume":"136","author":"L Malcovati","year":"2020","unstructured":"Malcovati L, Stevenson K, Papaemmanuil E, Neuberg D, Bejar R, Boultwood J, et al. SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the prognosis of MDS. Blood. 2020;136:157\u201370.","journal-title":"Blood"},{"key":"2262_CR18","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1038\/leu.2011.232","volume":"26","author":"V Visconte","year":"2012","unstructured":"Visconte V, Makishima H, Jankowska A, Szpurka H, Traina F, Jerez A, et al. SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts. Leukemia. 2012;26:542\u20135.","journal-title":"Leukemia"},{"key":"2262_CR19","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms. Leukemia. 2022;36:1703\u201319.","journal-title":"Leukemia"},{"key":"2262_CR20","doi-asserted-by":"publisher","first-page":"e125","DOI":"10.3324\/haematol.2014.119032","volume":"100","author":"S Jeromin","year":"2015","unstructured":"Jeromin S, Haferlach T, Weissmann S, Meggendorfer M, Eder C, Nadarajah N, et al. Refractory anemia with ring sideroblasts and marked thrombocytosis cases harbor mutations in SF3B1 or other spliceosome genes accompanied by JAK2V617F and ASXL1 mutations. Haematologica. 2015;100:e125\u2013127.","journal-title":"Haematologica"},{"key":"2262_CR21","doi-asserted-by":"publisher","first-page":"EVIDoa2200008","DOI":"10.1056\/EVIDoa2200008","volume":"1","author":"E Bernard","year":"2022","unstructured":"Bernard E, Tuechler H, Greenberg PL, Hasserjian RP, Arango Ossa JE, Nannya Y, et al. Molecular international prognostic scoring system for myelodysplastic syndromes. NEJM Evid. 2022;1:EVIDoa2200008.","journal-title":"NEJM Evid"},{"key":"2262_CR22","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2:401\u20134.","journal-title":"Cancer Discov"},{"key":"2262_CR23","first-page":"1128","volume":"90","author":"J Thiele","year":"2005","unstructured":"Thiele J, Kvasnicka HM, Facchetti F, Franco V, van der Walt J, Orazi A. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica. 2005;90:1128\u201332.","journal-title":"Haematologica"},{"key":"2262_CR24","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","volume":"120","author":"PL Greenberg","year":"2012","unstructured":"Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sol\u00e9 F, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120:2454\u201365.","journal-title":"Blood"},{"key":"2262_CR25","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/gcc.22510","volume":"57","author":"B Li","year":"2018","unstructured":"Li B, Liu J, Jia Y, Wang J, Xu Z, Qin T, et al. Clinical features and biological implications of different U2AF1 mutation types in myelodysplastic syndromes. Genes Chromosom Cancer. 2018;57:80\u201388.","journal-title":"Genes Chromosom Cancer"},{"key":"2262_CR26","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1182\/blood.2019004229","volume":"136","author":"L Palomo","year":"2020","unstructured":"Palomo L, Meggendorfer M, Hutter S, Twardziok S, Adem\u00e0 V, Fuhrmann I, et al. Molecular landscape and clonal architecture of adult myelodysplastic\/myeloproliferative neoplasms. Blood. 2020;136:1851\u201362.","journal-title":"Blood"},{"key":"2262_CR27","doi-asserted-by":"publisher","first-page":"101348","DOI":"10.1016\/j.eclinm.2022.101348","volume":"46","author":"Y Cui","year":"2022","unstructured":"Cui Y, Zhang J, Li Z, Wei K, Lei Y, Ren J, et al. A CT-based deep learning radiomics nomogram for predicting the response to neoadjuvant chemotherapy in patients with locally advanced gastric cancer: a multicenter cohort study. eClinicalMedicine. 2022;46:101348.","journal-title":"eClinicalMedicine"},{"key":"2262_CR28","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1016\/j.ijrobp.2021.07.1691","volume":"111","author":"MR McFarlane","year":"2021","unstructured":"McFarlane MR, Hochstedler KA, Laucis AM, Sun Y, Chowdhury A, Matuszak MM, et al. Predictors of pneumonitis after conventionally fractionated radiotherapy for locally advanced lung cancer. Int J Radiat Oncol Biol Phys. 2021;111:1176\u201385.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2262_CR29","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1002\/cac2.12067","volume":"40","author":"J Wu","year":"2020","unstructured":"Wu J, Zhang H, Li L, Hu M, Chen L, Xu B, et al. A nomogram for predicting overall survival in patients with low-grade endometrial stromal sarcoma: a population-based analysis. Cancer Commun. 2020;40:301\u201312.","journal-title":"Cancer Commun"},{"key":"2262_CR30","doi-asserted-by":"publisher","first-page":"E246","DOI":"10.1002\/ajh.26182","volume":"96","author":"G Montalban-Bravo","year":"2021","unstructured":"Montalban-Bravo G, Kanagal-Shamanna R, Darbaniyan F, Siddiqui MT, Sasaki K, Wei Y. et al. Clinical, genomic, and transcriptomic differences between myelodysplastic syndrome\/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS\/MPN-RS-T) and myelodysplastic syndrome with ring sideroblasts (MDS-RS). Am J Hematol. 2021;96:E246\u2013E249.","journal-title":"Am J Hematol"},{"key":"2262_CR31","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/s41379-020-0624-y","volume":"34","author":"CY Ok","year":"2021","unstructured":"Ok CY, Trowell KT, Parker KG, Moser K, Weinberg OK, Rogers HJ, et al. Chronic myeloid neoplasms harboring concomitant mutations in myeloproliferative neoplasm driver genes (JAK2\/MPL\/CALR) and SF3B1. Mod Pathol. 2021;34:20\u201331.","journal-title":"Mod Pathol"},{"key":"2262_CR32","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.3324\/haematol.2012.072538","volume":"98","author":"S Jeromin","year":"2013","unstructured":"Jeromin S, Haferlach T, Grossmann V, Alpermann T, Kowarsch A, Haferlach C, et al. High frequencies of SF3B1 and JAK2 mutations in refractory anemia with ring sideroblasts associated with marked thrombocytosis strengthen the assignment to the category of myelodysplastic\/myeloproliferative neoplasms. Haematologica. 2013;98:e15\u201317.","journal-title":"Haematologica"},{"key":"2262_CR33","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1038\/leu.2014.49","volume":"28","author":"J Bros\u00e9us","year":"2014","unstructured":"Bros\u00e9us J, Lippert E, Harutyunyan AS, Jeromin S, Zipperer E, Florensa L, et al. Low rate of calreticulin mutations in refractory anaemia with ring sideroblasts and marked thrombocytosis. Leukemia. 2014;28:1374\u20136.","journal-title":"Leukemia"},{"key":"2262_CR34","doi-asserted-by":"publisher","first-page":"e27","DOI":"10.1111\/bjh.16146","volume":"187","author":"T Inano","year":"2019","unstructured":"Inano T, Araki M, Morishita S, Imai M, Yasuda H, Nitta H, et al. JAK2 exon 12 mutation in myelodysplastic\/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis: not an exclusive mutation to polycythaemia vera. Br J Haematol. 2019;187:e27\u2013e31.","journal-title":"Br J Haematol"},{"key":"2262_CR35","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1038\/s41375-019-0574-x","volume":"34","author":"AA Mangaonkar","year":"2020","unstructured":"Mangaonkar AA, Swoboda DM, Coltro G, Lasho TL, Novotny PJ, Pophali P, et al. Clinicopathologic characteristics, prognostication and treatment outcomes for myelodysplastic\/myeloproliferative neoplasm, unclassifiable (MDS\/MPN-U): Mayo Clinic-Moffitt Cancer Center study of 135 consecutive patients. Leukemia. 2020;34:656\u201361.","journal-title":"Leukemia"},{"key":"2262_CR36","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.humpath.2022.08.007","volume":"129","author":"B Aqil","year":"2022","unstructured":"Aqil B, Sukhanova M, Behdad A, Jennings L, Lu X, Chen Q, et al. Many faces of SF3B1-mutated myeloid neoplasms: concurrent mutational profiles contribute to the diverse clinical and morphologic features. Hum Pathol. 2022;129:81\u201389.","journal-title":"Hum Pathol"},{"key":"2262_CR37","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, et al. International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140:1200\u201328.","journal-title":"Blood"},{"key":"2262_CR38","doi-asserted-by":"publisher","first-page":"e13229","DOI":"10.1111\/eci.13229","volume":"50","author":"EW Steyerberg","year":"2020","unstructured":"Steyerberg EW, Van Calster B. Redefining significance and reproducibility for medical research: a plea for higher P-value thresholds for diagnostic and prognostic models. Eur J Clin Investig. 2020;50:e13229.","journal-title":"Eur J Clin Investig"},{"key":"2262_CR39","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1002\/sim.8779","volume":"40","author":"C Wallisch","year":"2021","unstructured":"Wallisch C, Dunkler D, Rauch G, de Bin R, Heinze G. Selection of variables for multivariable models: opportunities and limitations in quantifying model stability by resampling. Stat Med. 2021;40:369\u201381.","journal-title":"Stat Med"},{"key":"2262_CR40","first-page":"20231261","volume":"290","author":"C Sutherland","year":"2023","unstructured":"Sutherland C, Hare D, Johnson PJ, Linden DW, Montgomery RA, Droge E. Practical advice on variable selection and reporting using Akaike information criterion. Proc Biol Sci. 2023;290:20231261.","journal-title":"Proc Biol Sci"},{"key":"2262_CR41","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1002\/ajh.26455","volume":"97","author":"MM Patnaik","year":"2022","unstructured":"Patnaik MM, Tefferi A. Chronic myelomonocytic leukemia: 2022 update on diagnosis, risk stratification, and management. Am J Hematol. 2022;97:352\u201372.","journal-title":"Am J Hematol"},{"key":"2262_CR42","doi-asserted-by":"publisher","first-page":"3106","DOI":"10.1182\/blood-2012-02-412296","volume":"120","author":"SJ Wu","year":"2012","unstructured":"Wu SJ, Kuo YY, Hou HA, Li LY, Tseng MH, Huang CF, et al. The clinical implication of SRSF2 mutation in patients with myelodysplastic syndrome and its stability during disease evolution. Blood. 2012;120:3106\u201311.","journal-title":"Blood"},{"key":"2262_CR43","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1038\/s41375-020-01106-z","volume":"35","author":"G Todisco","year":"2021","unstructured":"Todisco G, Creignou M, Gall\u00ec A, Guglielmelli P, Rumi E, Roncador M, et al. Co-mutation pattern, clonal hierarchy, and clone size concur to determine disease phenotype of SRSF2(P95)-mutated neoplasms. Leukemia. 2021;35:2371\u201381.","journal-title":"Leukemia"},{"key":"2262_CR44","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1038\/leu.2016.216","volume":"30","author":"MM Patnaik","year":"2016","unstructured":"Patnaik MM, Lasho TL, Finke CM, Hanson CA, King RL, Ketterling RP, et al. Vascular events and risk factors for thrombosis in refractory anemia with ring sideroblasts and thrombocytosis. Leukemia. 2016;30:2273\u20135.","journal-title":"Leukemia"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02262-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02262-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02262-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T08:07:23Z","timestamp":1717402043000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02262-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,7]]},"references-count":44,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["2262"],"URL":"https:\/\/doi.org\/10.1038\/s41375-024-02262-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3933186\/v1","asserted-by":"object"}]},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,7]]},"assertion":[{"value":"6 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"RPG is a consultant to NexImmune Inc, Nanexa Pharma, Ascentage Pharm Group and Antengene Biotech LLC. He is Medical Director of FFF Enterprises Inc., Partner in AZAC Inc., is on the Board of Directors of the Russian Foundation for Cancer Research Support and is a member of the Scientific Advisory Board of StemRad Ltd. The other authors have no relevant conflicts of interest to declare about the manuscript.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The patient gave written informed consent compliant with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}